<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140826</url>
  </required_header>
  <id_info>
    <org_study_id>ASARI-II</org_study_id>
    <nct_id>NCT03140826</nct_id>
  </id_info>
  <brief_title>Amplification and Selection of Antimicrobial Resistance in the Intestine II</brief_title>
  <acronym>ASARI II</acronym>
  <official_title>Amplification and Selection of Antimicrobial Resistance in the Intestine II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stool samples will be collected from two groups of neutropenic patients in the case that a
      therapy with either meropenem or piperacillin/tazobactam is needed due to a suspected
      infection. The intestinal resistome will be determined and quantified using shotgun
      metagenomics. Based on this, regression models will be used to determine the actual selection
      pressure caused by these drugs, and both selective forces will be compared. The results will
      reveal if there is a drug that causes a lower selection pressure compared to the other. The
      study aims to generate knowledge that is required to design effective antibiotic stewardship
      programs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibiotic Selection Pressure</measure>
    <time_frame>under treatment, max. 10 days</time_frame>
    <description>Degree of the change of the intestinal resistome.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Antibiotic Selection Pressure</condition>
  <arm_group>
    <arm_group_label>Meropenem arm</arm_group_label>
    <description>Patients receiving meropenem to treat an infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pip-Tazo arm</arm_group_label>
    <description>Patients receiving piperacillin-meropenem to treat an infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meropenem</intervention_name>
    <description>Antibiotics to treat infections.</description>
    <arm_group_label>Meropenem arm</arm_group_label>
    <other_name>piperacillin-tazobactam</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hemato-oncological disease in neutropenia or with expected neutropenia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hemato-oncological disease in neutropenia or with expected neutropenia

          -  Need for treatment with meropenem or piperacillin-tazobactam

        Exclusion Criteria:

          -  pregnancy

          -  HIV, HBV, HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Willmann, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Willmann, Prof. Dr.</last_name>
    <phone>+49 70712981527</phone>
    <email>matthias.willmann@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Vehreschild, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Microbiology and Hygiene, University Hospital of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Willmann, MD</last_name>
      <phone>+49 7071 29-81527</phone>
      <email>matthias.willmann@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Matthias Willmann</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

